A prevalent increase in antimicrobial resistance represents a universal obstacle for the treatment of Staphylococcus aureus (S. aureus) infection, especially in critically ill patients. Silver nanoparticles are defined as  broad spectrum bactericidal agents, which might be effective against vancomycin resistant S. aureus (VRSA). In this study, we  examined the bactericidal efficacy of silver nanoparticles on VRSA  in 150 blood and sputum samples isolated from intensive care patients. Methicillin resistant  S. aureus (MRSA) isolates were identified in 83 samples, with an incidence of 55.3%.  Meanwhile, VRSA isolates were found in 11 and 8 isolates (a total of 19 isolates out of 150) from sputum and blood samples, with an incidence of 14.67% and 10.67% respectively, with a total incidence of 12.67%. Vancomycin intermediate S. aureus (VISA) isolates had an inhibitory zone ranging from 9 to 13 mm, which was found in 13 out of 19 isolates, whereas VRSA isolates had an inhibitory zone ranging from 0 to 6 mm, which was detected  in 6 out of 19 isolates.  The findings of this study confirm that silver nanoparticles are effective treatment against VRSA.

Keywords: nanoparticles; vancomycin resistance; S. aureus.